Novel therapies for the treatment of inflammatory airway disease

Expert Opinion on Investigational Drugs

Volumn 12, Issue 1, 2003, Pages 5-18

  Hele, David J ^a   Belvisi, Maria G ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airway inflammation; Asthma; Chronic obstructive pulmonary disease; New approaches; Novel therapies

Indexed keywords

18 METHOXYCORONARIDINE; 2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMFEBUTAMONE; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRADYKININ ANTAGONIST; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CILOMILAST; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MEPOLIZUMAB; MOMETASONE FUROATE; MONTELUKAST; OMALIZUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHODIESTERASE IV INHIBITOR; PRANLUKAST; RECOMBINANT INTERLEUKIN 10; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ADRENAL INSUFFICIENCY; ASTHMA; BONE DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; GROWTH DISORDER; HEALTH CARE; HUMAN; NONHUMAN; PREVALENCE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SYMPTOMATOLOGY; VOMITING;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037234521     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.1.5     Document Type: Review

References (150)

1. BARNES PJ: New treatments for COPD. Nat. Rev. Drug Discov. (2002) 1:437-446.
2. JEFFERY PK: Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest (2000) 117:251S-260S.
3. BARNES PJ: Mechanisms in COPD: differences from asthma. Chest (2000) 117:10S-14S.
4. KERJSTENS HAM, GROEN HJ, VAN DER BIJ W: Recent advances in respiratory medicine. BMJ (2001) 323:1349-1353.
5. PAHL A, SZELENYI I: Asthma therapy in the new millennium. Infamm. Res. (2002) 51:273-282.
6. RUTTEN VAN-MOLKEN MP, FEENSTRA TL: The burden of asthma and, chronic obstructive pulmonary disease: data from The Netherlands. Pharmacoeconomics (2001) 19:1-6.
7. LOPEZ AD, MURRAY CC: The global burden of disease, 1990-2020. Nat. Med. (1998) 4:1241-1243.
8. BARNES PJ: New treatments for chronic obstructive pulmonary disease. Curr. Opin. Pharmacol. (2001) 1:217-222.
9. PAUWELS RA, BUIST S, CALVERLEY PM, JENKINS CR, HURD SS: Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. (2001) 163:1256-1276.
10. BARNES PJ: Chronic obstructive pulmonary disease. N. Eng. J. Med (2000) 343:269-280.
11. SAETTA M, TURATO G, MAESTRELLI P. MAPP CE, FABBRI LM: cellular and structural basis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 163:1304-1309.
12. SHAPIRO SD: End-stage chronic obstructive pulmonary disease: the cigarette is burned out but the inflammation rages on. Am. J. Respir. Crit. Care Med (2001) 164:339-340.
13. NATIONAL INSTITUTES OF HEALTH. NATIONAL HEART LUNG AND BLOOD INSTITUTE: Global initiative for asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. Publication Number 02-3659 (2002):16.
14. DJUKANOVIC R: Asthma: a disease of inflammation and repair. J. Allergy Clin. Immunol. (2000) 105:S522-S526.
15. BJERMER L: History and future perspectives of treating asthma as a systemic and small airway disease-Respir. Med. (2001) 95:703-719.
16. BARNES PJ: The Pharmacological properties of Tiotropium. Chest (2000) 117:63S-66S.
17. TAYLOR DA, JENSEN MW, KANABAR V et al.: A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5-monophosphate in asthmatic patients. Am. J. Respir. Crit. Care Med. (1999) 160:237-243.
18. DENT G: Ciclesonide (Byk Gulden). Curr. Opin. Investig. Drugs (2002) 3:78-83.
19. CASABURI R, MAHLER DA, JONES PW et al.: A long-term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Resp. J. (2002) 19:217-224.
20. VINCKEN W, VAN NOORD JA, GREEFHORST AP et al.: Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur. Resp. J. (2002) 19:209-216.
21. VAN NOORD JA, BANTJETA, ELAND ME, KORDUCKI L, CORNELLISSEN PJ: A randomised controlled comparison of notropium. and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax (2000) 55:289-294.
22. DONOHUE JF, VAN NOORD JA, BATEMAN ED et al.: A 6-month, placebo controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest (2002) 122:47-55.
23. MAHLER DA, WIRE R HORSTMAN D et al.: Effectiveness of fluticasone propionate, and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2002) 166:1084-1091.
24. JORENBY D: Clinical efficacy of bupropion in the management of smoking cessation. Drugs (2002) 62:25-35.
25. GLICK SD, MAISONNEUVE IM, KITCHEN BA: Modulation of nicotine self administration in rats by combination therapy with agents blocking α3β4 nicotinic receptors. Eur. J. Pharmacol. (2002) 448:185-191.
26. WILLIAMS TJ, JOSE PJ: Neutrophils in chronic obstructive pulmonary disease. Novartis Found. Symp. (2001) 234:136-141.
27. SILBAUGH SA, STENGEL PW, COCKERHAM SL et al.: Pharmacologic actions of the second generation leukotriene receptor antagonist LY293111: in vivo pulmonary studies. Naunyn-Schmiedebergs Arch. Pharmacol. (2000) 361:397-404.
28. LEE E, LINDOT, JACKSON N et al.: Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygense activating protein inhibitors. Am. J. Respir. Crit. Care Med. (1999) 160:2079-2085.
29. GOMPERTZ S, STOCKLEY RA: A randomised, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest (2002) 122:289-294.
30. YANG XD, CORVALAN JR, WANG P, ROY CM, DAVIS CG: Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukoc. Biol (1999) 66:401-410.
31. WOOLHOUSE IS, BAYLEY DL, STOCKLEY RA: Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax (2002) 57:709-714.
32. OWEN C: Chemokine receptors in airway disease: which receptors to target? Pulm. Pharmacol. Ther. (2001) 14:193-202.
33. HAY DW, SARAU HM: Interleukin-8-receptor antagonists in pulmonary diseases. Curr. Opin. Pharmacol. (2001) 1:242-247.
34. WHITE JR, LEE JM, YOUNG PR et al.: Identification of a potent, selective nonpeptide CXCR2 antagonist that inhibits interieukin-8-induced neutrophil migration. J. Biol Chem. (1998) 273:10095-10098.
35. AUTEN RL, RICHARDSON RM, WHITE JR, MASON SN, VOZZELLI MA, WHORTON MH: Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J. Pharmacol. Exp. Ther. (2001) 299:90-95.
36. DE BOER WI, SONT JK, VAN SCHADEWIJK A, STOLK J, VAN KRIEKEN JH, HIEMSTRA PS: Monocyte chemoattractant protein 1, interleukin 8 and chronic airways inflammation in COPD. J. Pathol. (2000) 190:619-626.
37. MAUS U, VON GROTE K, KUZIEL WA: The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. Am. J. Respir. Crit. Care Med. (2002) 166:268-273.
38. BOCCHINO V, BERTORELLI G, BERTRAND CP et al.: Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy (2002) 57:17-22.
39. KEATINGS VM, COLLINS PD, SCOTT DM, BARNES PJ: Differences in interleukin-8 and tumour necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. (1996) 153:530-534.
40. BLACK RA: Tumour necrosis factor-alpha converting enzyme. Int. J. Biochem. Cell Biol. (2002) 34:1-5.
41. TRIFILIEFF A, WALKER C, KELLER T, KOTTIRSCH G, NEUMANN U: Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br. J. Pharmacol. (2002) 135:1655-1664.
42. GIEMBYCZ MA: Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch. Chest Dis. (2002) 57:48-64.
43. GIEMBYCZ MA: Cilomilast: a second generation phosphodiesterase 4 inhbitor for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs (2001) 10:1361-1379.
44. REID P: Roflumilast Altana Pharma. Curr. Opin. Investig. Drugs (2002) 3:1165-1170.
45. STURTON G, FITZGERALD M: Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest (2002) 121:192S-196S.
46. COMPTON CH, GUBB J, NIEMAN R. Cilomilast, a selective phosphodiesterase-4 inhibitor for the treatment of patients with chronic obstructive pulmonary disease: a randomised, dose ranging study. Lancet (2001) 358:265-270.
47. GAMBLE E, PAVORD ID, VIGNOLA AM: Cilomilast (Ariflo®), a novel treatment for COPD, reduces the key inflammatory cells in bronchial biopsies. Am. J. Respir. Crit. Care Med. (2002) 165:A227.
48. KELSEN SG, YANG Y, BIN W, LI X, AKSOY MO: Cilomilast and salmeterol inhibit chemokine release by human airway epithelial cells. Am. J. Respir. Crit. Care Med. (2002) 165-A194.
49. LEICHTL S, SYED J, BREDENBROKER D, RATHGEB, WURST W: Efficacy of once-daily Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2002) 165:A229.
50. LAMONTAGNE S, MEADOWS E, LUK P: Localisation of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res. (2001) 920:84-96.
51. TRIFILIEFF A, WYSS D, WALKER C, MAZZONI L, HERSPERGER R. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]napthyridin-6-yl)-benzoic acid (NVPABE171), a 1,7-nathyridine derivative, with anti-inflammatory activities. J. Pharmacol. Exp. Ther. (2002) 301:241-248.
52. HADDAD EB, BIRRELL M, MCCLUSKIE K et al.: Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br. J. Pharmacol. (2001) 132:1715-1724.
53. UNDERWOOD DC, OSBORN RR, BOCHNOWICZ S et al.: SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell Mol. Physiol. (2000) 279:L895-L902.
54. SHAPIRO SD: Proteinases in chronic obstructive pulmonary disease. Biochem. Soc. Trans. (2002) 30:98-102.
55. NADEL J: Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest (2000) 117:386S-389S.
56. FITZGERALD ME, SPICER D, FOX C, KOBAYASHI DK, SHAPIRO S: Effect of acute and chronic exposures to cigarette smoke in two strains of mice. Efficacy of a matrix metalloproteinases (MMP) inhibitor, BAY 15-7496, on emphysema development. Am. J. Respir. Crit. Care Med. (2002) 165:A824.
57. CHURG A, ZAY K, SHAY S: Acute cigarette smoke induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Am. J Respir. Cell. Mol. Biol. (2002) 278:368-374.
58. RUSSEL RE, CULPITT SV, DEMATOS C et al.: Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Cell. Mol. Biol. (2002) 26:602-609.
59. WRIGHT JL, FARMER SG, CHURG A: Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am. J. Respir. Crit. Care Med. (2002) 166:954-960.
60. STOCKLEY RA, BAYLEY DL, UNSAL I, DOWSON LJ: The effect of augmentation therapy on bronchial inflammation in α-1-antitrypsin deficiency. Am. J. Respir Crit. Care Med. (2002) 165:1494-1498.
61. OHBAYASHI H: Neutrophil elastase inhibitors as treatment for COPD. Fxpert Opin. Investig. Drugs (2002) 11:965-980.
62. KURAKI T, ISHIBASHI M, TAKAYAMA M, SHIRAISHI M, YOSHIDA M: A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats. Am. J. Respir. Crit. Care Med. (2002) 166:496-500.
63. LEUNG-TOUNG R, LI W, TAM TF, KARIMIAN K: Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Chem. (2002) 9:979-1002.
64. MASSARO G, MASSARO D: Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med (1997) 3:675-677.
65. HIND M, MADEM M: A mouse model of alveolar regeneration. Am. J. Respir. Crit. Care Med (2002) 165-A223.
66. FRANKENBERGER M, HAUCK RW, FRANKENBERGER B: All trans retinoic acid selectively down-regulates matrix metalloproteinase-9 (MMP-9) and upregulates tissue inhibitor of meralloproteinase-1 (TIMP-1) in human bronchoalveolar lavage cells. Mol. Med. (2001) 7:263-270.
67. OFULUE A. Retinoids reverse cigarette smoke-induced emphysema in rats. Am. Respir. Cit. Care Med. (2002) 165-B7.
68. MAO C, BAILEY-HEALEY I, GATER PR, BELLONI P: Effects of RO444753, a synthetic retinoid agonist, on morphologic and lung function changes in a rat model of emphysema. Am. J. Respir. Crit. Care Med. (2002) 165:A825.
69. TODD G, DUNLOP K, MCNABOE J, RYAN MF, CARSON D, SHIELDS MD: Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet (1996) 348:27-29.
70. WHOL E, MAJZOOB J: Asthma, steroids and growth. N. Engl. J. Med. (2000) 343:1113-1114.
71. O'CONNOR BJ, SIPS P, ENGELSTATTER R, STEINIJANS VW, WURST W. Management of moderate to severe bronchial asthma by Ciclesonide: a 12 week trial. Am. J. Respir. Crit. Care Med. (2002) 165:A767.
72. CHAPMAN KR, D'URZO AD, OEDEKOVEN C, STEINIJANS VW, WURST W: Effects of Cidesonide versus placebo on lung function after 12 weeks of treatment in patients with asthma. Am. J. Respir. Crit. Care Med. (2002) 165:A767.
73. ENGELSTATTER R, LANGDON C, BETHKE T, RATHGEB F, STEINIJANS VW, WURST W: Inhaled corticosteroids: efficacy and adverse effects. Am. J. Respir. Crit. Care Med. (2002) 165-A766.
74. WEINBRENNER A, HUNEKE D, ZSCHIESCHE M et al.: Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J. Clin. Endocrinol. Metab. (2002) 87:2160-2163.
75. 20 for adenosine in asthma patients. Am. J. Respir. Crit. Care Med (2002) 165-A768.
76. FOZARD JR, MANLEY PW: Potassium channel openers: agents for the treatment of airway hyperreactivity. In: New drugs for asthma, allergy and COPD (Vol. 31). TT Hansel, PJ Barnes (Eds), Karger, Basel, Switzerland (2001):77-80.
77. BUCHHEIT KH, MANLEY PW, QUAST U, RUSS U, MAZZONI L, FOZARD JR: KCO912: a potent and selective opener of ATP-dependent potassium (K(ATP)) channels which suppresses airways hyperreactivity at doses devoid of cardiovascular effects. Naunyn-Schmiederbergs Arch. Pharmacol. (2002) 365:220-230.
78. LARCHE M, TILL SJ, HASELDEN BM et al.: Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. J. Immunol. (1998) 161:6375-6382.
79. VAN OOSTERHOUT AJ, HOFSTRA CL, SHIELDS R. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in murine model of allergic asthma. Am. J. Respir. Cell. Mol. Biol. (1997) 17:386-392.
80. DEURLOO DT, VAN ESCH BC, HOFSTRA CL, NIJKAMP FP, VAN OOSTERHOUT AJ: CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model. Am. J. Respir. Cell Mol. Biol. (2001) 25:751-760.
81. NORMAN PS: Immunotherapy: past and present. (1998) J. Allergy Clin. Immunol. 102:1-10.
82. HANSEL TT, BARNES PJ: Novel drugs for treating asthma. Curr. Allergy Asthma Rep. (2001) 1:164-173.
83. LARCHE M: Anti-T-cell strategies in the treatment of allergic disease. Allergy (2002) 57:20-23.
84. FICK RB: Anti-IgE as novel therapy for the treatment of asthma. Curr. Opin. Pulm. Med. (1999) 5:76-80.
85. TUMAS DB, CHAN B, WERTHER W et al.: Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitisation. Allergy Clin. Immunol. (2001) 107:1025-1033.
86. BERGER WE: Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease. Ann. Allergy Asthma Immunol. (2002) 8:152-160.
87. HOLGATE S, BOUSQUET J, WENZEL S, FOX H, LIU J: Omalizumab improves disease control in patients at high risk of serious asthma-related morbidity and mortality. Am. J. Respir. Crit. Care Med. (2002) 165:A187.
88. BOUSQUET J, HOLGATE S, WENZEL S, FOX H, LIU J: Omalizumab reduces the incidence and frequency of exacerbations in patients at high risk of serious asthma-related morbidity and mortality. Am. J. Respir. Crit. Care Med. (2002) 165:A187.
89. WENZEL S, BOUSQUET J, HOLGATE S, FREEMAN P, FOX H: Patients with more severe allergic asthma gain greatest relative benefit from omalizumab therapy. Am. J. Respir. Crit. Care Med. (2002) 165:A215.
90. MCMILLAN RM: Leukotrines in respiratory disease. Paediatr. Respir. Rev. (2001) 2:238-244.
91. DUCHARME FM: Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ (2002) 324:1545-1552.
92. BORISH L: The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. Ann. Allergy Asthma Immunol. (2002) 88:16-22.
93. CRETICOS P, KNOBIL K, EDWARDS LD, RICKARD KA, DORINSKY P: Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann. Allergy Asthma Immunol. (2002) 88:401-409.
94. BUSSE W, NELSON H, WOLFE J, KALBERG C, YANCEY SW, RICKARD KA: Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J. Allergy Clin. Immunol. (1999) 103:1075-1080.
95. HART PH: Regulation of the inflammatory response in asthma by mast cell products. Immunol. Cell Biol. (2001) 79:149-153.
96. AKERS IA, PARSONS M, HILL MR et al.: Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am. J. Physiol. Lung Cell Mol. Physiol. (2000) 278:L193-L201.
97. SYLVIN H, DAHLBACK M, VAN DER PLOEG I, ALVING K. The tryptase inhibitor APC-366 reduces the acute airway response to allergen in pigs sensitised to Ascaris suum. Clin. Exp. Allergy (2002) 32:967-971.
98. WRIGHT CD, HAVILL AM, MIDDLETON SC et al.: Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[3-cabamimidoyl-benzenesulfonylamino)-methyl]phenoxy-pentane (AMG-126737). Biochem. Pharmacol. (1999) 58:1989-1996.
99. OH SW, PAE CI, LEE DK et al.: Tryptase inhibition blocks airway inflammation in a mouse asthma model. J. Immunol. (2002) 168:1992-2000.
100. KRISHNA MT, CHAUHAN A, LITTLE L et al.: Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J. Allergy Clin. Immunol. (2001) 107:1039-1045.
101. LECKIE MJ, TEN BRINKE A, KHAN J et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 356:2144-2148.
102. KIPS JC, TOURNOY KG, PAUWELS RA: New asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5. Eur. Respir. J. (2001) 17:499-506.
103. SUN Q, JONES K, MCCLURE B et al.: Simultaneous antagonism of IL-5, granulocyte-macrophage colony stimulating factor, and IL-3 stimulation of human eosinophils by targeting the common cytokine binding site of their receptors. Blood(1999) 94:1943-1951.
104. RAMSHAW HS, WOODCOCK JM, BAGLEY CJ, MCCLURE BJ, HERCUS TR, LOPEZ AF: New approaches in the treatment of asthma. Immunol. Cell Biol. (2001) 79:154-159.
105. BORISH LC, NELSON HS, CORREN J et al.: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. (2001) 107:963-970.
106. TOMKINSON A, DUEZ C, CIESLEWICZ G et al.: A murine IL,4 receptor antagonist that inhibits IL-4 and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J. Immunol. (2001) 166:5792-5800.
107. FOSTER PS, MARTINEZ-MOCZYGEMBA M, HUSTON DP, CORRY DB: Interleukins-4,-5, and -13: emerging therapeutic targets in allergic disease. Pharmacol. Ther. (2002) 94:253-264.
108. MULLINGS RE, WILSON SJ, PUDDICOMBE SM et al.: Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. J. Allergy Clin. Immunol. (2001) 108:832-838.
109. TAYLOR PC: Anti-tumour necrosis factor therapies. Curr. Opin. Rheumatol. (2001) 13:164-169.
110. FERNANDEZ-BOTRAN R, CRESPO FA, SUN X: Soluble cytokine receptors in biological therapy. Expert Opin. Biol. Ther. (2002) 2:585-605.
111. WEISMAN MH: What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J. Rheumatol Suppl. (2002) 65:33-38.
112. BARNES PJ: Cytokine modulators as novel therapies for asthma. Ann. Rev. Pharmacol. Toxicol. (2002) 42:81-98.
113. HANSEN G, BERRY G, DEKRUYFF RH, UMETSU DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J. Clin. Invest. (1999) 103:175-183.
114. BRYAN SA, O'CONNOR BJ, MATTI S et al.: Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 356:2149-2153.
115. PRETOLANI M, GOLDMAN M: IL-10: a potential therapy for allergic inflammation? Immunol. Today (1997) 18:277-280.
116. FEDORAK RN, GANGL A, ELSON CO et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology (2000) 119:1473-1482.
117. PROUDFOOT AE: Chemokine receptors: multifaceted therapeutic targets. Nat. Rev. Immunol. (2002) 2:106-115.
118. BERTRAND CP, PONATH PD: CCR3 blockade as a new therapy for asthma. Expert Opin. Invest. Drugs (2000) 9:43-52.
119. WHITE JR, LEE JM, DEDE K et al.: Identification of potent, selective nonpeptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2, and monocyte chemotactic protein-4-induced eosinophil migration. J. Biol. Chem. (2000) 275:626-631.
120. SABROE I, PECK MJ, VAN KEULEN BJ et al.: A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. (2000) 275:985-992.
121. WACKER DA, SANTELLA III JB, GARDNER DS et al.: CCR3 antagonists: A potential new therapy for the treatment of asthma. Discovery and structure-activity relationship. Bioorg. Med. Chem. Lett. (2002) 12:1785-1789.
122. D'AMBROSIO D, MARIANI M, PANINA-BORDIGNON P, SINIGAGLIA F: Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am. J. Respir. Crit. Care Med. (2001) 164:1266-1275.
123. GATER P, SATJAWATCHARAPHONG C, STALEY C, SZCZEPANSKI K, KERTESZ D, BERTRAND CP: Effect of orally active CCR3 antagonists in animal models of allergic airway inflammation. Am. J. Repir. Crit. Care Med (2002) 165:A313.
124. CAMPBELL EM, CHARO IF, KUNKEL SL et al.: Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/- mice: the role of mast cells. J. Immunol. (1999) 163:2160-2167.
125. LLOYD CM, DELANEY T, NGUYEN T et al.: CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med. (2000) 191:265-274.
126. TIMMER W, LECLERC V, BIRRAUX G et al.: The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNFα ex vivo. J. Clin. Pharmacol. (2002) 42:297-303.
127. LEICHTL S, SCHMID-WIRLITSCH C, BREDENBROKER D, RATHGEB F, WURST W: Dose-related efficacy of once-daily Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in asthma. Am. J. Respir Crit. Care Med. (2002) 165:A185.
128. CARTER AB, MONICK MM, HUNNINGHAKE GW: Both erk and p38 kinases are necessary for cytokine gene transcription. Am. J. Respir. Cell Mol. Biol. (1999) 20:751-758.
129. LEE JC, KUMAR S, GRISWOLD DE et al.: Inhibition of p38 MAP kinase as a therapeutic strategy Immunopharmacology (2000) 47:185-201.
130. BIRRELL M, HELE D, MCCLUSKIE K et al.: Effect of p38 kinase inhibitor, SB 203580, on sephadex induced airway inflammation in the rat. Eur. Respir. 1 (2000) 16:947-950.
131. UNDERWOOD DC, OSBORN RR, KOTZER CJ et al.: SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J. Pharmacol. Exp. Ther. (2000) 293:281-288.
132. IRUSEN E, MATTHEWS JG, TAKAHASHI A, BARNES PJ, CHUNG KF, ADCOCK IM: p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J. Allergy Clin. Immunol. (2002) 109:649-657.
133. FOZARD JR, HANNON JP: Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD. Pulm. Pharmacol. Ther. (1999) 12:111-114.
134. HOLGATE ST: Adenosine: a key effector molecule of asthma or just another mediator? Am. J. Physiol. Lung Cell Mol. Physiol. 282:L167-L168.
135. FOZARD JR. MCCARTHY C: Adenosine receptor ligands as potential therapeutics in asthma. Curr. Opin. Investig. Drugs (2002) 3:69-77.
136. SANDRASAGRA A, LEONARD SA, TANG L et al.: Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. (2002) 12:177-181.
137. FOZARD JR, ELLIS KM, VILLELA DANTAS MF, TIGANI B, MAZZONI L: Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur. J. Pharmacol. (2002) 438:183-188.
138. GLAXOSMITHKLINE PLC: Product development pipeline February 2001. Company brochure (22 February, 2001).
139. EZEAMUZIE CI: Involvement of A(3) receptors in the potentiation by adenosine of the inhibitory effect of theophylline on human eosinophil degranulation: possible novel mechanism of the anti-inflammatory action of theophylline. Biochem. Pharmacol. (2001) 61:1551-1559.
140. SERHAN CN, DEVCHAND PR: Novel anti-inflammatory targets for asthma. A role for PPARγ? Am. J. Respir. Cell Mol. Mol. (2001) 24:658-661.
141. WANG AC, DAI X, LUU B, CONRAD DJ: Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am. J. Repir. Cell Mol. Biol. (2001) 24:688-693.
142. BENAYOUN L, LETUVE S, DRUILHE A et al.: Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am. J. Respir. Crit. Care Med. (2001) 164:1487-1494.
143. OATES JC, REILLY CM, CROSBY MB, GS GILKESON: Peroxisome proliferator-activated receptor γ agonists: potential use for treating chronic inflammatory diseases. Arthritis Rheum. (2002) 46:598-605.
144. BONNANS C, VACHIER I, CHAVIS C, GODARD P, BOUSQUET J, CHANEZ: Lipoxins are potential endogenous anti-inflammatory mediators in asthma. Am. J. Respir. Crit. Care Med. (2002) 165:1531-1535.
145. 4. Nat. Med. (2002) 8:1018-1023.
146. KLINE JN: DNA therapy for asthma. Curr. Opin. Allergy Clin. Immunol. (2002) 2:69-73.
147. BELVISI MG: Overview of the innervation of the lung. Curr. Opin. Pharmacol. (2002) 2:211-215.
148. CHUNG KF: Cough: potential pharmacological developments. Expert Opin. Investig. Drugs. (2002) 11:955-963.
149. SPINA D, PAGE CP: Pharmacology of airway irritability. Curr. Opin. Pharmacol. (2002) 2:264-272.
150. BIRRELL MA, CRISPINO N, HELE DJ et al.: Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets. Br. J. Pharmacol. (2002) 136:620-628.